Photodynamic Therapy for Early Head and Neck Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01019954|
Recruitment Status : Completed
First Posted : November 24, 2009
Last Update Posted : November 10, 2014
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Tumors||Drug: Levulan||Phase 1|
The primary objectives of the study are to evaluate the toxicities associated with Levulan®-mediated photodynamic therapy in pre-malignant head and neck lesions, and to evaluate the toxicities of continuous vs. fractionated light treatment. The secondary objectives are to assess the efficacy of Levulan®-mediated photodynamic therapy in pre-malignant head and neck lesions, and to assess the efficacy of fractionated versus continuous light treatment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Official Title:||Photodynamic Therapy for Premalignant and Early Stage Head and Neck Tumors|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||November 2014|
- PDT related toxicity.
- lesion response.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01019954
|United States, Pennsylvania|
|Abramson Cancer Center of the University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|